More importantly, treatment with clinically available inhibitors targeting Src or HSP90 was found to suppress primary tumor growth, circulation in the blood, and metastatic tumor development of 5-FU-resistant cancer cells in vivo. This evidence concerns the gene SRC and neoplasm.